PEMBROLIZUMAB-RELATED BILATERAL OCULAR HYPOTONY ASSOCIATED WITH CILIARY DETACHMENTS AND MACULA OEDEMA: A TREATMENT-RESISTANT SIDE EFFECT.
Louise BecCharles KhouriChristophe Chiquet
Published in: Retinal cases & brief reports (2024)
Pembrolizumab treatment carries a risk of ocular hypotony which can be bilateral, presenting a challenging risk - benefit dilemma, particularly if pembrolizumab is effective in controlling the cancer.